Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 4/20 | 0.44 |
| ▸ | TSPO | P30536 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035139 | 0.99 | P2RY14 (0.44) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6036244 | 0.83 | P2RY14 (0.50) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6034581 | 0.82 | P2RY14 (0.51) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6035135 | 0.80 | PPARD (0.43) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6035871 | 0.79 | PPARD (0.44) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL2120020 | 0.76 | NOTUM (0.64) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL6034453 | 0.74 | P2RY14 (0.52) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL1219816 | 0.73 | NOTUM (0.47) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL11484346 | 0.73 | P2RY14 (0.47) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 | |
| SCHEMBL2904708 | 0.73 | NOTUM (0.64) | P2RY14TSPOCYP2C9TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | P2RY14 3559/4885TSPO 1258/4885CYP2C9 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.